Background: The condition of COVID-19-related myocarditis has emerged as a prominent contributor to COVID-19 mortality. As the epidemic persists, its incidence continues to rise. Despite ongoing efforts, the elucidation of COVID-19-related myocarditis underlying molecular mechanisms still requires further investigation.
Methods: Hub genes for COVID-19-related myocarditis were screened by integrating gene expression profile analysis via differential expression in COVID-19 (GSE196822) and myocarditis (GSE148153 and GSE147517). After verification with independent datasets (GSE211979, GSE167028, GSE178491 and GSE215865), the hub genes were studied using a range of systems-biology approaches, such as ceRNA, TF-mRNA networks and PPI networks, as well as gene ontology, pathway enrichment, immune infiltration analysis and drug target identification.
Results: TBKBP1 and ERGIC1 were identified as COVID-19-related myocarditis hub genes via integrated bioinformatics analysis. In addition, receiver operating characteristic curves constructed based on the expression levels of TBKBP1 and ERGIC1 could effectively distinguish healthy control individuals from patients with COVID-19. Functional enrichment analysis suggested several enriched biological pathways related to inflammation and immune response. Immune cell changes correlated with TBKBP1 and ERGIC1 levels in patients with COVID-19 or patients with COVID-19 and myocarditis. Tamibarotene, methotrexate and theophylline were identified as a potential drug targeting TBKBP1 and ERGIC1.
Conclusion: TBKBP1 and ERGIC1 were identified as crucial genes in the development of COVID-19-related myocarditis and have demonstrated a strong association with innate antiviral immunity. The present work may be helpful for further investigation of the molecular mechanisms and new therapeutic drug targets correlated with myocarditis in COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.micpath.2024.106587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 and PIMS-TS-related admissions to paediatric intensive care in the Republic of Ireland January 2020 and July 2022 and analysis of cardiovascular manifestations of their disease.
Cardiol Young
October 2024
Paediatric Intensive Care Department and Children's heart centre, Children's Health Ireland at Crumlin, Dublin, Republic of Ireland.
Article Synopsis
- Researchers studied children in Ireland admitted to pediatric ICU for COVID-19 or related conditions between January 2020 and August 2022 to understand illness severity and outcomes.
- Out of 127 children, the majority had acute COVID-19 (68.5%) or Pediatric Inflammatory Multisystem Syndrome (30.7%), with those in the PIMS-TS group requiring more intensive cardiac support.
- Despite the high incidence of cardiac issues during hospitalization, all patients survived and showed normal heart function upon discharge.
Two causes of COVID-19-related myocardial injury-associated cardiogenic shock: Myocarditis and microvascular thrombosis.
ESC Heart Fail
November 2024
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Serum endocan (ESM-1) as diagnostic and prognostic biomarker in Multisystem inflammatory syndrome in children (MIS-C).
Cytokine
December 2024
Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy; CEINGE-Biotecnologie Avanzate S.c.a.r.l., Naples, Italy.
Article Synopsis
- Endothelial-cell-specific molecule-1 (ESM-1), also known as endocan, is identified as a significant biomarker for inflammation and cardiovascular risk in COVID-19 patients, particularly in the context of Multisystem Inflammatory Syndrome in children (MIS-C).
- In a study comparing ESM-1 levels between MIS-C patients and healthy controls, MIS-C patients showed significantly higher levels of ESM-1, suggesting its potential diagnostic value.
- The research indicates that ESM-1 not only correlates with other inflammatory markers but is also associated with cardiac complications, highlighting its role in assessing cardiovascular risks in MIS-C patients and aiding in treatment strategies.
The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study.
Heart
November 2024
Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Article Synopsis
- Patients with congenital heart disease (CHD) are at higher risk for severe COVID-19 outcomes, and this study assesses how vaccination impacts their risk levels.* -
- A case-control study compared unvaccinated and vaccinated CHD patients' COVID-19 outcomes, finding that post-vaccination CHD patients had significantly lower hospitalization (0.5% vs 15.8%) and death rates (0.5% vs 4.6%).* -
- Despite the improvements after vaccination, CHD patients remained at an increased risk of hospitalization and death compared to vaccinated controls, with no indication of faster decline in vaccine efficacy or higher rates of complications.*
In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.
Eur J Pediatr
December 2024
Grupo de Investigación Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria (NEMECS), Universidad Científica del Sur, Lima, Perú.
Unlabelled: Studies on the severity in multisystem inflammatory syndrome in children (MIS-C) show heterogeneous results and may not reflect a global perspective. This systematic review aims to estimate the frequency of in-hospital unfavorable outcomes in patients with MIS-C over the 3 years since the onset of the SARS-CoV-2 pandemic. A systematic search was conducted in Medline, Scopus, Embase, Cochrane, Web of Science, Scielo, and preprint repositories until December 15, 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!